0RIS Stock Overview
A clinical stage cancer immunotherapy and RNA therapeutics company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Circio Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr11.20 |
| 52 Week High | kr37.20 |
| 52 Week Low | kr11.12 |
| Beta | 2.06 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -96.14% |
| 5 Year Change | -95.71% |
| Change since IPO | -96.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RIS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 0.1% |
| 1Y | n/a | -21.6% | 6.4% |
Return vs Industry: Insufficient data to determine how 0RIS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0RIS performed against the UK Market.
Price Volatility
| 0RIS volatility | |
|---|---|
| 0RIS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RIS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0RIS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 17 | Erik Wiklund | www.circio.com |
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system.
Circio Holding ASA Fundamentals Summary
| 0RIS fundamental statistics | |
|---|---|
| Market cap | kr56.45m |
| Earnings (TTM) | -kr449.26m |
| Revenue (TTM) | kr10.00m |
5.6x
P/S Ratio-0.1x
P/E RatioIs 0RIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RIS income statement (TTM) | |
|---|---|
| Revenue | kr10.00m |
| Cost of Revenue | kr0 |
| Gross Profit | kr10.00m |
| Other Expenses | kr459.26m |
| Earnings | -kr449.26m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 15, 2024
| Earnings per share (EPS) | -62.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,491.69% |
| Debt/Equity Ratio | -135.9% |
How did 0RIS perform over the long term?
See historical performance and comparison